← 返回

亚油酸通过 PPAR-α/TF 轴驱动肺淋巴上皮瘤样癌进展

英文原题:Linoleic acid drives pulmonary lymphoepithelioma-like carcinoma progression via PPAR-α/TF axis.

查看英文原题

Linoleic acid drives pulmonary lymphoepithelioma-like carcinoma progression via PPAR-α/TF axis.

PubMed 2025/08/15(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

本研究表明,LA 通过 PPAR-α/TF 轴重塑 pLELC 肿瘤微环境,提示 TF 可作为 pLELC 的潜在治疗靶点。

研究思路结论见上方概要

原发性肺淋巴上皮瘤样癌(pLELC)是一种罕见的非小细胞肺癌(NSCLC)亚型,其病因机制尚不明确。本研究旨在探讨pLELC的潜在分子机制和治疗靶点。

回顾性收集晚期pLELC患者的样本进行蛋白质组学和代谢组学分析,并建立患者来源异种移植(PDX)模型进行验证。数据非依赖性采集(DIA)定量蛋白质组学揭示pLELC中组织因子(TF)蛋白表达上调,而非靶向代谢组学鉴定出亚油酸(LA)等关键代谢物。

结果表明,LA通过促进M2型肿瘤相关巨噬细胞浸润和抑制自然杀伤(NK)细胞活性来推动肿瘤进展,这些效应可被TF抑制剂Tisotumab逆转。机制研究表明,LA通过过氧化物酶体增殖物激活受体α(PPAR-α)增强TF表达,而TF抑制剂能有效抵消LA诱导的恶性表型。

展开英文摘要原文

Primary pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare subtype of non-small cell lung cancer(NSCLC) with unclear etiological mechanisms. This study aimed to investigate the underlying molecular mechanisms and therapeutic targets for pLELC.

Retrospectively collected samples from advanced pLELC patients underwent proteomic and metabolomic analyses, and patient-derived xenograft (PDX) models were established for validation. Data-independent acquisition (DIA) quantitative proteomics revealed upregulated tissue factor (TF) protein expression in pLELC, while untargeted metabolomics identified key metabolites such as linoleic acid (LA).

Results demonstrated that LA promotes tumor progression by facilitating M2-type tumor-associated macrophage infiltration and suppressing natural killer (NK) cell activity, effects reversible by the TF inhibitor Tisotumab. Mechanistic studies indicated that LA enhances TF expression via peroxisome proliferator-activated receptor α (PPAR-α), and TF inhibitors effectively counteract LA-induced malignant phenotypes.

This study reveals that LA remodels the pLELC tumor microenvironment through the PPAR-α/TF axis, suggesting TF as a potential therapeutic target for pLELC.

论文信息

作者
Bao H、Zhang J、Chen Z、Wang Y、Wang Z、Chen Z、Jiang T、Zhang B
第一作者单位
Department of Oncology, The Affiliated Panyu Center Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.China
通讯作者单位
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.China
期刊
Frontiers in oncology2025
原文标识
PubMed 40896442 · DOI 10.3389/fonc.2025.1640201